These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 12732687)

  • 1. Investigating dopaminergic neurotransmission with 123I-FP-CIT SPECT: comparability of modern SPECT systems.
    Meyer PT; Sattler B; Lincke T; Seese A; Sabri O
    J Nucl Med; 2003 May; 44(5):839-45. PubMed ID: 12732687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys.
    Booij J; Andringa G; Rijks LJ; Vermeulen RJ; De Bruin K; Boer GJ; Janssen AG; Van Royen EA
    Synapse; 1997 Nov; 27(3):183-90. PubMed ID: 9329154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.
    O'Brien JT; Colloby S; Fenwick J; Williams ED; Firbank M; Burn D; Aarsland D; McKeith IG
    Arch Neurol; 2004 Jun; 61(6):919-25. PubMed ID: 15210531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
    Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
    Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproducibility of a standardized quantitative analysis using fixed regions of interest to differentiate movement disorders on 123I-FP-CIT SPECT.
    Stokkel MP; Dibbets-Schneider P; Koestering E; Dragoiescu C; Blokland KA
    J Nucl Med Technol; 2007 Mar; 35(1):21-6. PubMed ID: 17337653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies.
    Koch W; Radau PE; Hamann C; Tatsch K
    J Nucl Med; 2005 Jul; 46(7):1109-18. PubMed ID: 16000279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
    Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
    J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FP-CIT and MIBG scintigraphy in early Parkinson's disease.
    Spiegel J; Möllers MO; Jost WH; Fuss G; Samnick S; Dillmann U; Becker G; Kirsch CM
    Mov Disord; 2005 May; 20(5):552-61. PubMed ID: 15645531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of semiquantitative analysis for clinical reporting of 123I-2-β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane SPECT studies.
    Söderlund TA; Dickson JC; Prvulovich E; Ben-Haim S; Kemp P; Booij J; Nobili F; Thomsen G; Sabri O; Koulibaly PM; Akdemir OU; Pagani M; van Laere K; Asenbaum-Nan S; George J; Sera T; Tatsch K; Bomanji J
    J Nucl Med; 2013 May; 54(5):714-22. PubMed ID: 23492885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT.
    Abi-Dargham A; Gandelman MS; DeErausquin GA; Zea-Ponce Y; Zoghbi SS; Baldwin RM; Laruelle M; Charney DS; Hoffer PB; Neumeyer JL; Innis RB
    J Nucl Med; 1996 Jul; 37(7):1129-33. PubMed ID: 8965183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.
    Di Giuda D; Calcagni ML; Totaro M; Cocciolillo F; Piano C; Soleti F; Fasano A; Cioni B; Bentivoglio AR; Giordano A
    Nucl Med Commun; 2012 Sep; 33(9):933-40. PubMed ID: 22735298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitation of dopamine transporter blockade by methylphenidate: first in vivo investigation using [123I]FP-CIT and a dedicated small animal SPECT.
    Nikolaus S; Wirrwar A; Antke C; Arkian S; Schramm N; Müller HW; Larisch R
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):308-13. PubMed ID: 15791440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.
    Booij J; Speelman JD; Horstink MW; Wolters EC
    Eur J Nucl Med; 2001 Mar; 28(3):266-72. PubMed ID: 11315592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
    Ishikawa T; Dhawan V; Kazumata K; Chaly T; Mandel F; Neumeyer J; Margouleff C; Babchyck B; Zanzi I; Eidelberg D
    J Nucl Med; 1996 Nov; 37(11):1760-5. PubMed ID: 8917170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease.
    Booij J; Tissingh G; Winogrodzka A; Boer GJ; Stoof JC; Wolters EC; van Royen EA
    Eur J Nucl Med; 1997 Jan; 24(1):68-71. PubMed ID: 9044880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects.
    Booij J; de Jong J; de Bruin K; Knol R; de Win MM; van Eck-Smit BL
    J Nucl Med; 2007 Mar; 48(3):359-66. PubMed ID: 17332612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iodine-123 labelled N-(2-fluoroethyl)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain.
    Kuikka JT; Akerman K; Bergström KA; Karhu J; Hiltunen J; Haukka J; Heikkinen J; Tiihonen J; Wang S; Neumeyer JL
    Eur J Nucl Med; 1995 Jul; 22(7):682-6. PubMed ID: 7498231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.